RxDoctor Payments Data

Clara Shnaidman, MD

Internal Medicine · Amsterdam, NYNPI 1801050117

Payments from drug & device makers

$2,159in general payments, 2019–2025

Across 100 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$355
  • AbbVie$316
  • Novo Nordisk$256
  • Pfizer$207
  • Astellas Pharma US Inc$190
  • GSK$162
  • plus $674 from 17 others

What the payments were for

  • Consulting fees$1758%
  • Food & beverage$1,89088%
  • Education$944%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,159 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$24,013
Medicare patients
73
Services billed
231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide100$107,365
JardianceEmpagliflozin49$68,110
FarxigaDapagliflozin Propanediol32$44,760
EliquisApixaban37$37,315
InvokanaCanagliflozin28$36,398
RybelsusSemaglutide24$28,467
OzempicSemaglutide30$27,407
MyrbetriqMirabegron18$23,233
MounjaroTirzepatide16$16,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,890
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$10,780
VascepaIcosapent Ethyl24$8,984
Breo ElliptaFluticasone/Vilanterol14$8,028
Repatha SureclickEvolocumab11$5,870
Spiriva RespimatTiotropium Bromide11$5,683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$66$124,103116 claims
Boehringer IngelheimJardiance, Spiriva Respimat$103$73,79360 claims
Novo NordiskRybelsus, Ozempic$256$55,87354 claims
AstraZenecaFarxiga, Symbicort$104$49,89254 claims
PfizerEliquis$207$37,31537 claims
Astellas Pharma US IncMyrbetriq$190$23,23318 claims
GSKTrelegy Ellipta, Breo Ellipta$162$20,91834 claims
MerckBelsomra$84$5,13212 claims
AbbVieSynthroid$316$2,70537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Amsterdam

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →